Protocatechuic Acid (Hydroxybenzoic Acid · Neuroprotective · Antioxidant)

Compound	Protocatechuic Acid (PCA)
Chemical class	Polyphenol — Hydroxybenzoic Acid (3,4-Dihydroxybenzoic Acid)
CAS	99-50-3
Primary source	Terminalia spp. (haritaki, bibhitaki), Hibiscus sabdariffa, many plant foods
Key applications	Antioxidant, neuroprotective, anti-inflammatory, metabolic
Claim strength	Moderate
Typical form	Tannin-rich botanical extract co-constituent; PCA isolate
Buy from Herbuno	Terminalia Bellirica (Bibhitaki) Extract Powder → Bahera Liquid Extract (Water Soluble) - Terminalia Bellirica →

Name origin: From the catechol (pyrocatechol) hydroxylation pattern at positions 3 and 4 of the benzoic acid ring — hence proto-catechuic (the founding catechol-type hydroxybenzoic acid). PCA is a primary metabolite of cyanidin-3-glucoside and other anthocyanins, formed by gut microbial and hepatic O-demethylation and hydrolysis. It is also a direct constituent of numerous tannin-rich plant preparations. Traditional use: As a constituent of Triphala (haritaki, bibhitaki, amalaki), PCA is indirectly part of one of Ayurveda’s most widely used formulations, prescribed for digestive, hepatic, antioxidant, and anti-ageing applications. Hibiscus calyx preparations, also rich in PCA, have traditional cardiovascular use in African and Caribbean medicine. Research trajectory: PCA has a well-characterised preclinical evidence base for neuroprotection (SIRT1/Nrf2), anti-inflammatory (NF-κB), antidiabetic, and hepatoprotective mechanisms. It is also the primary circulating metabolite after consumption of cyanidin-3-glucoside (elderberry, blackberry), making it pharmacologically relevant far beyond its direct dietary sources. Commercial source: Available as a co-constituent of Terminalia and Hibiscus extracts; isolated PCA is available from specialist suppliers. See sourcing options below.

---

Evidence for Protocatechuic Acid Applications

Neuroprotective activity: PCA activates SIRT1 and Nrf2/HO-1 in neural cell models, reducing oxidative stress and neuroinflammation. In rodent ischaemia-reperfusion models, PCA reduces infarct volume and improves neurological scores. As the primary metabolite of elderberry anthocyanins, PCA may explain a significant portion of the cognitive benefits attributed to anthocyanin-rich botanical extracts. Claim strength: Moderate.

Anti-inflammatory: PCA inhibits NF-κB and reduces TNF-α, IL-6, and COX-2 in macrophage and epithelial models. In vivo anti-inflammatory efficacy in arthritis, colitis, and lung injury animal models is well-documented. Claim strength: Moderate.

Antidiabetic and metabolic: PCA activates AMPK, improves insulin sensitivity, and reduces hepatic gluconeogenesis in animal models of type 2 diabetes. Human data from dietary PCA exposure studies (via anthocyanin-rich foods) show correlations with improved metabolic biomarkers. Claim strength: Moderate.

---

Dosage & Formulator Specification

No established isolated human supplement dose for PCA. Estimated systemic PCA exposure after anthocyanin-rich food/supplement consumption: 10–50 mg/day as a circulating metabolite, even without direct PCA supplementation. For direct PCA delivery, tannin-standardised Terminalia extracts (haritaki, bibhitaki) at 200–500 mg/day provide meaningful PCA alongside gallic acid, ellagic acid, and chebulic acid. Isolated PCA is available from specialist suppliers (≥98% HPLC).

PCA is highly water-soluble and orally bioavailable. Absorbed efficiently in the small intestine; plasma Tmax ~1 hour. Stable at acidic to neutral pH. Compatible with all standard supplement formats including aqueous liquids. Not light-sensitive; standard packaging is adequate.

---

Frequently Asked Questions — Protocatechuic Acid

Is PCA the reason elderberry anthocyanins are bioactive despite low direct absorption?
Partly yes. Cyanidin-3-glucoside (C3G), the primary elderberry anthocyanin, has very low intact oral bioavailability (<1–2%). The primary circulating metabolite after C3G consumption is PCA, produced by gut microbial hydrolysis and hepatic metabolism. PCA reaches plasma concentrations substantially higher than intact C3G and may account for a significant portion of the systemic antioxidant, anti-inflammatory, and neuroprotective effects attributed to elderberry and other anthocyanin-rich preparations.

How does PCA differ from gallic acid structurally and functionally?
PCA (3,4-dihydroxybenzoic) has two adjacent hydroxyls (catechol pattern). Gallic acid (3,4,5-trihydroxybenzoic) has three. The additional hydroxyl in gallic acid provides higher antioxidant capacity and metal chelation. Both inhibit NF-κB and share anti-inflammatory mechanisms. PCA has better-characterised neuroprotective activity via SIRT1 activation; gallic acid has superior antimicrobial activity. Both are dietary phenolic acids with overlapping but distinct profiles.

Is PCA from Triphala preparations bioavailable?
Yes. PCA is released from galloyl esters in Triphala constituents (haritaki, bibhitaki, amalaki) by gut enzymatic hydrolysis of gallotannins. PCA is then absorbed in the small intestine. Human pharmacokinetic studies after Triphala consumption show measurable plasma PCA, though quantitation varies by preparation and individual gut microbial profile.

Can PCA be positioned as a standalone neuroprotective supplement ingredient?
PCA has strong mechanistic plausibility for neuroprotection but limited isolated human clinical evidence. It is most practically positioned as a component of broad-spectrum botanical antioxidant blends or as part of the bioactive explanation for why anthocyanin-rich and tannin-rich botanical preparations demonstrate systemic effects beyond their modest intact absorption.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery